Shares of Tourmaline Oil Corp. TOU advanced 1.44% to C$61.21 Friday, in what proved to be an all-around positive trading ...

Shares of Tourmaline Oil Corp. TOU slipped 0.92% to C$60.34 Thursday, in what proved to be an all-around down trading session ...

Tourmaline Bio, Inc.’s TRML share price has dipped by 7.00%, which has investors questioning if this is right time to buy.

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline ...

Tourmaline Oil stands out as a compelling natural gas investment with strong fundamentals, shareholder returns, and a ...

In December 2024, Tourmaline announced the over-enrollment of its Phase 2 TRANQUILITY trial, which evaluates quarterly and monthly subcutaneous dosing of pacibekitug in patients with elevated high ...

Energy stocks remain my portfolio's most frustrating group. Click here to read why I see opportunity amid the chaos.

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 - - Tourmaline ...

Tourmaline Oil Corp. (TRMLF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fintel reports that on April 23, 2025, Chardan Capital initiated coverage of Tourmaline Bio (NasdaqGS:TRML) with a Buy ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Tourmaline Oil Corp. (TRMLF) reports results for the quarter ended March 2025. While this widely-known consensus ...